Google Releases Rebuilt Gemini 3.5 Pro, Moonshot AI Debuts 2.8T Kimi K3, and AI Uncovers Massive Cancer Research Paper Mill Fraud

Google Releases Rebuilt Gemini 3.5 Pro, Moonshot AI Debuts 2.8T Kimi K3, and AI Uncovers Massive Cancer Research Paper Mill Fraud
Three stories from July 17, 2026 reveal AI's expanding reach — from model architecture to the integrity of science itself. Google DeepMind's Gemini 3.5 Pro is the first major frontier release where a lab scrapped completed base weights and restarted pretraining from scratch due to recursive tool-calling failures — signalling that agentic reliability is now a hard requirement, not a post-launch tuning problem. Moonshot AI's Kimi K3 (2.8T parameters, 896 experts, 16 active per query, Kimi Delta Attention achieving 2.5× efficiency vs K2) is the largest open-weight model ever released and the first to match frontier closed models in agentic reasoning benchmarks at $3/M input tokens. And a Queensland University of Technology (QUT) BERT classifier scanned 2.6 million cancer research papers published 1999–2024, flagging 250,000+ as paper mill frauds — rising from <1% of published papers in 2000 to over 16% in 2022 — with 91% classification accuracy validated against known retracted papers.
🤖 Gemini 3.5 Pro — Why Google Restarted Pretraining from Scratch
The Tool-Calling Failure That Forced the Rebuild
Why recursive tool-calling is hard: Standard text generation (completing a prompt) is a single-pass operation. Recursive tool-calling is a loop:
| Step | Action | Failure mode |
|---|---|---|
| 1 | Model generates function call A | Hallucinated parameter names |
| 2 | Tool A executes; returns result | — |
| 3 | Model receives result; generates function call B using A's output as input | Misinterprets A's output schema |
| 4 | Tool B executes; returns result | — |
| 5 | Model uses B's output to generate C | Error compounding: A's misinterpretation propagates through B → C |
| 6+ | Cascade continues | Model enters hallucinatory loop: calls tools with nonsense parameters indefinitely |
Gemini's initial base model had structural issues at steps 3 and 5 — when receiving tool outputs and using them as inputs to subsequent tool calls, the model incorrectly parsed the schema of intermediate results, causing cascading hallucinations in deep tool chains.
Why Google restarted instead of patching: Post-training fixes (RLHF, SFT on corrected examples) can mitigate surface-level hallucinations but cannot fix structural architectural issues in how the model's attention layers attend to intermediate tool outputs. The problem was diagnosed as originating in the base pretraining weights — not fixable by fine-tuning.
Timeline of the rebuild:
| Date | Event |
|---|---|
| Original target | Mid-May 2026 |
| Internal evaluation reveals recursive tool-calling failure | May 2026 |
| Decision to scrap base weights and restart pretraining | Late May 2026 |
| Restart pretraining from scratch | May–June 2026 |
| Gemini 3.5 Pro public launch | July 17, 2026 |
| Delay | ~8 weeks |
The precedent: Google chose an 8-week delay over shipping a broken agentic model. This is the first documented case of a frontier lab scrapping completed pretraining weights due to tool-use failures — indicating the industry now treats agentic reliability as a launch blocker, not a post-launch problem.
Gemini 3.5 Pro Specifications
Technical specs:
| Specification | Gemini 3.5 Pro | Previous (Gemini 3.0 Pro) |
|---|---|---|
| Context window | 2,000,000 tokens | 1,000,000 tokens |
| Native multimodality | Text + image + video + audio + code | Text + image + video |
| Reasoning mode | "Deep Think" (extended test-time compute) | Standard only |
| Tool-calling reliability | Rebuilt from scratch — significantly improved | Buggy in nested chains |
| GPQA Diamond | ~80% | ~72% |
| Pricing | $14/M input, $42/M output (Deep Think) | $12/M input, $35/M output |
| Available via | Gemini API, Google AI Studio, Vertex AI | Same |
The "Deep Think" mode — what it does: Deep Think is Gemini 3.5 Pro's extended reasoning mode (similar to OpenAI's o3 thinking mode):
- Allocates additional test-time compute before generating the final response
- The model runs internal hypothesis generation and testing (not visible to user, but increases response latency by ~3–8 seconds)
- Trade-off: ~3× slower → ~15–20% more accurate on complex reasoning, coding, and agentic benchmarks
🌐 Kimi K3 — 2.8T MoE, 896 Experts, Open Weights
MoE Architecture at 2.8T Scale
Mixture-of-Experts (MoE) — why it enables this scale: In a standard dense model, every parameter is active for every forward pass:
- 2.8T dense model: all 2.8T parameters fire for every token → inference requires moving 2.8T parameters through memory → infeasible
In an MoE model, the model has N expert sub-networks, but only K experts activate per token:
- Kimi K3: 896 total experts, 16 active per query
- Active parameters per forward pass: ~60B (comparable to a dense 60B model)
- But knowledge capacity: encoded across all 896 experts ≈ 2.8T parameters worth of knowledge
Kimi K3 vs dense model economics:
| Model | Parameters | Active per pass | Inference memory | Inference FLOPS |
|---|---|---|---|---|
| Dense 70B | 70B | 70B | ~140 GB | High |
| Dense 200B | 200B | 200B | ~400 GB | Very high |
| Kimi K3 (MoE 2.8T) | 2.8T | ~60B | ~120 GB (active) | Similar to dense 60B |
| GPT-5 (est. dense) | ~1T | ~1T | ~2 TB | Extremely high |
Kimi Delta Attention (KDA) — the efficiency innovation:
| Problem | Standard attention mechanism | KDA solution |
|---|---|---|
| KV cache growth | KV cache grows linearly with context → at 1M tokens, KV cache is enormous | KDA: linear attention for long-range; standard attention for local context |
| Memory bandwidth | Reading full KV cache for each token generation = bandwidth bottleneck | KDA + attention residuals: 2.5× reduction in KV cache memory access |
| Long-context performance | Standard attention degrades at >200K tokens | KDA maintains performance across full 1M token context |
Kimi K3 benchmarks vs proprietary frontier:
| Benchmark | Kimi K3 | GPT-5.5 | Claude Fable | Gemini 3.5 Pro |
|---|---|---|---|---|
| GPQA Diamond | 79.4% | ~78% | ~77% | ~80% |
| SWE-Bench (coding) | 68.2% | ~72% | ~70% | ~69% |
| AIME 2025 (math) | 92.1% | ~89% | ~87% | ~91% |
| HumanEval | 95.6% | ~94% | ~93% | ~95% |
Kimi K3 is within benchmark noise of the best closed proprietary models — for the first time, open weights = frontier quality.
Pricing and availability:
| Tier | Price | Context |
|---|---|---|
| API (Kimi platform) | $3/M input tokens, $15/M output | vs GPT-5.5: $12/M input |
| Open weights | MIT license, weights public July 27, 2026 | Self-host; full fine-tuning access |
| Inference cost (self-hosted, GPU cluster) | ~$0.20/M tokens | vs API: 15× cheaper at scale |
The MIT license + weights public = any developer can download and deploy Kimi K3 with full fine-tuning access.
🔬 BERT Paper Mill Audit — 250K Fraudulent Cancer Papers
The Academic Paper Mill Industrial Complex
What paper mills are and how they work:
| Operation | Description |
|---|---|
| Fabrication | Generate fictional research data; create plausible-looking tables/graphs from non-existent experiments |
| Dataset recycling | Reuse the same underlying dataset across multiple papers with different author names and slightly varied framing |
| Image manipulation | Alter Western blot images, microscopy photos, or flow cytometry data to create "new" results |
| Authorship sales | Sell authorship slots to researchers who need publication credits for career advancement (promotions, grants, visa applications) |
| Template production | Use fill-in-the-blank paper templates — the same structure, same references, same phrasing — published with different "experimental results" |
Why cancer research is particularly vulnerable:
- High-volume field (2.6M papers 1999–2024 = ~100,000+ papers/year)
- Complex experimental methods (cell cultures, animal models, molecular assays) that are difficult for peer reviewers to verify without repeating the experiments
- High pressure to publish in competitive research environments (China, Iran, Egypt — countries with high identified paper mill activity per the BMJ study)
The BERT classifier — technical approach:
| Step | Method | What it detects |
|---|---|---|
| 1. Training data | Known retracted papers (confirmed paper mill) + verified genuine papers | Classifier learns to distinguish authentic from fraudulent writing |
| 2. Textual fingerprints | Model identifies: boilerplate phrasing, repetitive formatting templates, stylistic inconsistencies | "Results section is 90% identical to 15 other papers with different reported cell lines" |
| 3. Statistical anomalies | Impossible p-values, suspicious data distributions, digit preference in reported numbers | Numbers that couldn't arise from genuine experimental variation |
| 4. Metadata cross-correlation | Same author, same institution, submitted within days of each other — across multiple journals | Industrial-scale production patterns |
| 5. Similarity clustering | Embeddings of paper sections clustered → papers sharing templates cluster together | Template reuse detection |
Scale of the findings — the 25-year fraud trajectory:
| Year range | Estimated paper mill % of published cancer papers | Interpretation |
|---|---|---|
| 1999–2005 | <1% | Paper mills existed but were small and unsophisticated |
| 2006–2014 | 1–5% | Growing — internet + online journal explosion |
| 2015–2020 | 5–12% | Rapid growth — academic pressure intensifies, mills professionalise |
| 2022 (peak) | >16% | More than 1 in 6 published cancer papers flagged as fraudulent |
| 2023–2024 | 12–14% | Declining slightly — publisher interventions + retractions |
Impact on oncology research: Papers flagged as paper mill productions have been cited in subsequent research — meaning fraudulent results have propagated into meta-analyses, clinical trial designs, and drug development decisions. If a drug was developed based on a fabricated pre-clinical result, it may have reached Phase I/II trials on a false premise, wasting billions in R&D and potentially exposing patients to ineffective treatments.
Publisher adoption of the BERT classifier: Following the BMJ publication, multiple major scientific publishers announced integration of the BERT classifier into editorial pipelines:
- Elsevier: Integrating as a mandatory pre-review screening step for journals with historically high retraction rates
- Springer Nature: Testing in oncology journal submissions
- Wiley: Evaluating for cell biology + cancer biology journals
The classifier does not reject papers — it flags them for mandatory enhanced human review (second independent peer reviewer + raw data request from authors).
📌 The Bottom Line
- gemini-3-5-pro-rebuilt-deep-think-2m-context: First documented case of frontier lab scrapping completed pretraining weights due to agentic reliability failure: recursive tool-calling cascade (A's misinterpretation propagates through B→C→... hallucinatory loop); structural attention-layer issue = not patchable by RLHF; 8-week delay over launching broken agent; specs: 2M context (2× prev), Deep Think mode (3× slower, 15-20% more accurate), 3× nesting tool-call reliability improvement; GPQA Diamond ~80%.
- kimi-k3-2-8t-moe-896-experts-kda: MoE economics: 896 experts, 16 active per query → ~60B active parameters (dense-60B inference cost) but 2.8T knowledge capacity; Kimi Delta Attention: linear attention for long-range + standard for local = 2.5× KV cache memory reduction; benchmarks within noise of best closed models (GPQA Diamond 79.4% vs GPT-5.5 ~78%); MIT license, weights public July 27, 2026; API $3/M input (vs GPT-5.5 $12/M); self-hosted ~$0.20/M.
- cancer-paper-mill-bert-250k-fraud: QUT BERT classifier: trained on retracted (confirmed mill) + genuine papers → detects textual fingerprints (boilerplate, template reuse, stylistic inconsistency), statistical anomalies (impossible p-values), metadata cross-correlation (same author/institution multi-journal same-day pattern), similarity clustering; 2.6M papers scanned, 250K+ flagged (91% accuracy against known retractions); fraud trajectory: <1% (1999-2005) → >16% (2022 peak) — 1 in 6 published cancer papers in 2022 fraudulent; fabricated pre-clinical results cited in meta-analyses + clinical trial designs = potential drug R&D decisions built on false premises; Elsevier/Springer Nature/Wiley integrating as mandatory pre-review screening.
📬 Stay Updated
Get the best of AI & technology delivered to your inbox every week. Subscribe to our free newsletter →
Disclosure: This post contains affiliate links. If you purchase through our links, we earn a small commission at no extra cost to you. We only recommend products we believe in.
Enjoyed this post?
Get our weekly digest delivered free.
Share this post:
Knowelth is reader-supported. We may earn a commission from links in this article at no extra cost to you. Read our disclosure.


